Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Clinical Research in Viral Hepatitis
share announcement

Clinical Research in Viral Hepatitis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 15 September 2024 | Viewed by 1652

Special Issue Editors

Dr. Nadia Marascio

E-Mail Website
Guest Editor
Department of Health Sciences, Clinical Microbiology Unit, “Magna Graecia” University, Catanzaro, Italy
Interests: clinical virology; viral pathogenesis; HCV drug resistance; classic and molecular epidemiology; micro-biome and metagenome analysis; infectious diseases; microbiology; viral hepatitis; HIV; antibiotic re-sistance
Special Issues, Collections and Topics in MDPI journals
Dr. Angela Quirino

E-Mail Website
Guest Editor
Associate Professor, Department of Health Sciences, Clinical Microbiology Unit, “Magna Graecia” University, Catanzaro, Italy
Interests: antibiotic resistance; infectious disease; pathogenic mechanisms; bacteriology; virology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Viral hepatitis is responsible for chronic infections and deaths in millions of cases worldwide. The hepatitis B (HBV) and hepatitis C (HCV) viruses remain major sources of morbidity and mortality globally, and HBV/hepatitis D virus (HDV) coinfection worsen the symptoms of hepatic disease. Furthermore, acute viral hepatitis is one of the most common infectious illnesses due to the hepatitis A (HAV) and hepatitis E (HEV) viruses.

The World Health Organization’s (WHO) global hepatitis strategy is estimated to reduce new infections and deaths between 2016 and 2030. In this regard, a new vaccine is under development (HEV), a new therapy is available (HDV), and virological screenings are ongoing (HCV and HBV). Seven years remain if we are to achieve the target of the viral hepatitis program proposed by the WHO. Nevertheless, the global burden of viral hepatitis remains severe, especially in low-income countries.

In light of this discussion, we are delighted to announce the upcoming Special Issue of Clinical Medicine entitled “Clinical Research in Viral Hepatitis”. This Special Issue aims to discuss clinical outcomes for people living with viral hepatitis and new relevant research in this field. We invite scholars to submit original research, communications, and review articles. We look forward to receiving your evaluable scientific contributions.

Dr. Nadia Marascio
Dr. Angela Quirino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HCV
  • HBV
  • HDV
  • HEV
  • HAV
  • clinical issues
  • antiviral resistance
  • clinical outcome

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 889 KiB  
Article
HBV in Italian Women’s Jail: An Underestimated Problem?
by Nicholas Geremia, Federico Giovagnorio, Andrea De Vito, Luca Martignago, Vito Fiore, Elena Rastrelli, Giordano Madeddu, Saverio Giuseppe Parisi, Giulio Starnini, Sandro Panese and Sergio Babudieri
J. Clin. Med. 2024, 13(5), 1398; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm13051398 - 28 Feb 2024
Viewed by 470
Abstract
Background: There is little information regarding the hepatitis B virus (HBV), vaccination status, and hepatitis B exposure in Italian women’s jails. We aimed to describe the HBV exposure and HBs antibody (anti-HBs) protection levels in female prisoners. Material and methods: A retrospective multicentric [...] Read more.
Background: There is little information regarding the hepatitis B virus (HBV), vaccination status, and hepatitis B exposure in Italian women’s jails. We aimed to describe the HBV exposure and HBs antibody (anti-HBs) protection levels in female prisoners. Material and methods: A retrospective multicentric study was performed in Italian prisons from 2021 to 2023. Univariate and multivariate analyses were conducted to identify risk factors for HBc antibody (anti-HBc) seropositivity and non-protective anti-HBs titer. Results: We included 156 patients. The median age was 41.0 (IQR 34.0–48.0). Of the studied subjects, 31 (19.9%) had anti-HBc positive titer. Two women were HBsAg positive. In the multivariate analysis, older age [OR 1.06 (CI 1.01–1.11), p = 0.011], North-Eastern European [OR 11.67 (3.29–41.30), p < 0.001] and African origin [OR 6.92 (CI 1.51–31.60), p = 0.013], and drug use [OR 6.55 (CI 1.96–21.9), p = 0.002] were risk factors for HBV exposure. Thirty-seven (32%) women had no history of HBV vaccination. Forty-four (38%) had an anti-HBs non-protective titer. In the multivariate analysis, North-Eastern European origin [OR 4.55 (CI 1.19–17.50), p = 0.027] was associated with unprotective anti-HBs titer. Conclusion: Our results show both the low prevalence of HBV and protection in female prisoners. Age, North-Eastern European and African origin, and drug use have a role in exposure risk to HBV. Full article
(This article belongs to the Special Issue Clinical Research in Viral Hepatitis)
►▼ Show Figures

Figure 1

12 pages, 1361 KiB  
Article
Hepatitis Flares or Hepatic Decompensation after Discontinuation of Tenofovir Disoproxil Fumarate and Entecavir in Non-Cirrhotic Hepatitis B e Antigen-Negative Patients
by Yi-Jie Huang, Tsai-Chung Li, Cheng-Hsu Chen, Chung-Hsin Chang, Szu-Chia Liao, Shou-Wu Lee, Yen-Chun Peng, Teng-Yu Lee and Jun-Sing Wang
J. Clin. Med. 2023, 12(24), 7565; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12247565 - 08 Dec 2023
Viewed by 915
Abstract
Hepatic events can occur after discontinuing antiviral therapy. We investigated factors associated with hepatitis flares and hepatic decompensation after discontinuing tenofovir disoproxil fumarate (TDF) and entecavir (ETV). Hepatitis flares within 6 months and hepatic decompensation were compared between non-cirrhotic hepatitis B e antigen-negative [...] Read more.
Hepatic events can occur after discontinuing antiviral therapy. We investigated factors associated with hepatitis flares and hepatic decompensation after discontinuing tenofovir disoproxil fumarate (TDF) and entecavir (ETV). Hepatitis flares within 6 months and hepatic decompensation were compared between non-cirrhotic hepatitis B e antigen-negative patients after discontinuing TDF or ETV by using the Cox proportional hazard model. The cumulative rates of hepatitis flare at 6 months after discontinuing ETV and TDF were 2% and 19%, respectively (p < 0.001). The respective rates of hepatic decompensation at 6 months were 0% and 7% (p = 0.009). Higher alanine aminotransferase (ALT) (AASLD criteria) at the end of treatment (EOT) (HR = 4.93; p = 0.001), an off-therapy dynamic change in HBV DNA (rapid rebound of HBV DNA from the nadir, ≥1 log10 IU/mL per month) (HR = 10.7; p < 0.001), and the discontinuation of TDF (HR = 6.44; p = 0.006) were independently associated with hepatitis flares within 6 months. Older age (HR = 1.06; p < 0.001) and an off-therapy dynamic change in HBV DNA (HR = 3.26; p = 0.028) were independently associated with hepatic decompensation after the discontinuation of antiviral therapy. In summary, we demonstrated several factors associated with hepatitis flares and hepatic decompensation after discontinuing antiviral therapy in non-cirrhotic hepatitis B e antigen-negative patients. Full article
(This article belongs to the Special Issue Clinical Research in Viral Hepatitis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop